Head to Head Contrast: Neumora Therapeutics (NMRA) & Its Competitors
Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) is one of 295 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Neumora Therapeutics to related businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. Analyst […]
More Stories
Stifel Nicolaus Forecasts Strong Price Appreciation for CyberArk Software (NASDAQ:CYBR) Stock
CyberArk Software (NASDAQ:CYBR – Get Free Report) had its price objective boosted by analysts at Stifel Nicolaus from $335.00 to...
Stifel Nicolaus Issues Positive Forecast for DigitalOcean (NYSE:DOCN) Stock Price
DigitalOcean (NYSE:DOCN – Get Free Report) had its target price raised by analysts at Stifel Nicolaus from $35.00 to $40.00...
News from the WHO: President Macron, WHO Director-General, and global health leaders inaugurate WHO Academy in Lyon https://ift.tt/IPbFCsE December 18, 2024 at 07:00AM
Published on December 18, 2024 at 07:00AM View on website
Acupuncture Proven Effective for Sciatica: Clinical Trial
By Jessica Lee Sciatica is a notoriously difficult condition to treat, with limited success from both conservative therapies and surgical...
Fastly (NYSE:FSLY) Shares Gap Up – Still a Buy?
Fastly, Inc. (NYSE:FSLY – Get Free Report)’s share price gapped up before the market opened on Wednesday . The stock...
Unum Group (NYSE:UNM) Given New $82.00 Price Target at Piper Sandler
Unum Group (NYSE:UNM – Get Free Report) had its target price boosted by analysts at Piper Sandler from $74.00 to...